Lithium inhibits neurite growth and tau protein kinase I/glycogen synthase kinase-3beta-dependent phosphorylation of juvenile tau in cultured hippocampal neurons.
Tau protein kinase I(TPKI)/glycogen synthase kinase (GSK)-3beta is abundant in the developing rat brain. The highly phosphorylated juvenile form of tau is present during the same developmental period. To study the role of TPKI/ GSK-3beta in neuronal growth, we examined the effects of lithium, a direct inhibitor of TPKI/GSK-3beta, using primary cultures of rat hippocampal neurons. Immunohistochemical staining of the neurons indicates that in the presence of lithium (2-10 mM), neurite growth becomes inhibited in a dose-dependent manner. Western blot analyses of the cell extracts revealed that the presence of lithium in the culture medium increased the amount of dephosphorylated tau while decreasing phosphorylation at Ser199 and Ser396, both of which are TPKI/GSK-3beta phosphorylation sites on tau. The inhibition by lithium is reversible. Although the amount of TPKI/GSK-3beta remained constant, the amount of tau decreased in a dose-dependent manner in the presence of lithium. TPKI/GSK-3beta was distributed in the somata and proximal neurites of the cultured hippocampal neurons. These results therefore suggest that TPKI/GSK-3beta plays an important role in the axonal growth of neurons during synapse formation in the developing brain.
Takahashi
M
M
Integrative Projects Center, Mitsubishi Kasei Institute of Life Sciences, Tokyo, Japan.
Yasutake
K
K
Tomizawa
K
K
D000818:Animals; D015153:Blotting, Western; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D002478:Cells, Cultured; D003598:Cytoskeletal Proteins / Q000378:metabolism; D004622:Embryo, Mammalian; D004791:Enzyme Inhibitors / Q000494:pharmacology; D038362:Glycogen Synthase Kinase 3; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism* / Q000648:ultrastructure; D018021:Lithium Chloride / Q000494:pharmacology*; D016501:Neurites / Q000187:drug effects / Q000502:physiology*; D009474:Neurons / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D010766:Phosphorylation; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D051381:Rats; D015534:Trans-Activators; D051176:beta Catenin; D016875:tau Proteins / Q000378:metabolism*
C495268:Ctnnb1 protein, rat; D003598:Cytoskeletal Proteins; D004791:Enzyme Inhibitors; D015534:Trans-Activators; D051176:beta Catenin; D016875:tau Proteins; D017346:Protein Serine-Threonine Kinases; D017871:Calcium-Calmodulin-Dependent Protein Kinases; D038362:Glycogen Synthase Kinase 3; C080888:tau-protein kinase; D018021:Lithium Chloride